The market taxonomy for anti‑CRP antibodies also reflects diversification by molecular type. Polyclonal antibodies, derived from immunized animals, dominate the cost‑sensitive segment and contribute roughly 35 % of unit sales due to their broad epitope coverage. Monoclonal antibodies, produced via hybridoma or recombinant platforms, command premium pricing and represent about 30 % of revenue, driven by superior batch‑to‑batch consistency required for diagnostic kits. Recombinant antibody fragments such as Fab and scFv provide enhanced tissue penetration and lower immunogenicity, accounting for an estimated 15 % of the market, particularly in point‑of‑care platforms. Humanized antibodies are engineered to reduce host immune response, supporting clinical‑trial biomarker applications and delivering approximately 12 % of total income. Finally, chimeric antibodies combine murine variable regions with human constant domains, occupying a niche of roughly 8 % focused on early‑stage drug‑discovery programs. The proportional contribution of each type determines manufacturing strategy, pricing models, and competitive positioning within the anti‑CRP antibody market. Emerging affinity‑maturation technologies are expected to shift share toward recombinant formats, potentially increasing their market proportion over the next five years.
